ICLR: Bull Flag detected on 21 Aug 2026

The bull flag pattern is forming after ICON's Q2 2026 results, where revenue edged up to $2,063.49 million while net income and earnings per share declined. At $174.26, the stock sits just below key resistance at $181.82 with strong structure (15/15) and breakout quality (12.5/13). Volume at 516K shares trades below the 20-day average (63% ratio), signaling light participation into the flag. The overall score of 83.9/98 and win probability of 76.73% indicates a solid but not exceptional setup. Support lies at $150.85—a 14.54% drop to reach.

Icon announced a multi-year collaboration with Anthropic to embed Claude's AI models into its Orbis platform, aiming to apply advanced automation and reasoning across clinical trial planning, execution, and protocol design. The direct fee book-to-bill ratio stands at 1.2x, underscoring strength in focused commercial strategy, while backlog reached $23.4 billion, up 3.0% on quarter one 2026. However, Q2 2026 results highlight tension: revenue ticked up, but net income and EPS fell sharply, even as management reaffirmed full year revenue guidance. The key catalyst is whether earnings quality improves, while the biggest risk remains contract volatility and pricing pressure. The three-month gain of 51.41% reflects recovery from accounting disclosure pressures earlier in 2026.

A successful bull flag breakout above $181.82 would target $180.01 per the conservative measure, though the proximity suggests limited measured-move extension room—the pattern may be working in real-time. Volume confirmation is critical; the current 0.63 volume ratio indicates breakout power remains weak. Invalidation occurs on a close below $150.85, representing a 13.4% risk zone. At 76.73% win probability, historical data shows three of four comparable setups in this sector advance post-breakout, though low volume during flag formation tempers confidence versus higher-conviction patterns.

Sharp drop in net income and confirmed control weaknesses keep accounting and execution risk front and center, with disclosed revenue recognition issues and material weaknesses in internal controls. Contract volatility and pricing pressure across biotech and large pharma customers remain the biggest risk; the Anthropic collaboration targets operational efficiency at a time when margins and pricing power are under strain. RSI at 59.34 shows neutral momentum with room to extend, while low relative volume (0.63) during flag consolidation raises questions about institutional conviction through breakout. The health care sector trades in bullish regime (0.92 score), but macro remains neutral, limiting sector tailwinds.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.